Rezolute, Inc. (NASDAQ: RZLT) met with the U.S. Food and Drug Administration (FDA) on March 17 2026 to review the results of its Phase 3 sunRIZE trial for congenital hyperinsulinism. The company reported clinically meaningful reductions in hypoglycemia events and time spent in hypoglycemia, but the primary endpoint did not reach statistical significance.
Continue reading for full analysis...